

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Biologics Evaluation and Research (CBER)  
171st Meeting of the Vaccines and Related Biological Products Advisory  
Committee  
Silver Spring, MD  
March 3, 2022  
AGENDA**

**Topic:** The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2022 – 2023 influenza season.

Time	Presentation/Presenter
<p><b>9:00am – 9:10am</b></p>    <p><b>9:10am – 9:30am</b></p>	<p><b><u>Opening Remarks: Call to Order, Introduction of Committee</u></b></p> <p><b>Hana El Sahly, M.D., Chair, VRBPAC</b> Professor, Dept. of Mol. Virology, Microbiology and Medicine Baylor College of Medicine</p> <p><b><u>Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 Min)</u></b></p> <p><b>Prabhakara Atreya, PH.D.</b> Acting Designated Federal Officer, VRBPAC CBER, FDA</p>
<p><b>9:30am – 9:45am</b></p>	<p><b><u>Introduction (15 min)</u></b></p> <p><b>Jerry Weir, Ph.D. (10 Min)</b> Director Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRR) CBER, FDA</p> <p>Q &amp;A: 5 min</p>
<p><b>9:45am – 10:10am</b></p>	<p><b><u>U.S. Surveillance (25 Min)</u></b></p> <p><b>Lisa Grohskopf, M.D., M.P.H. (20 Min)</b> CAPT., USPHS Associate Chief for Policy &amp; Liaison Activities Epidemiology &amp; Prevention Branch, Influenza Division Centers for Disease Control and Prevention (CDC)</p> <p>Q &amp;A: 5 min</p>

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Biologics Evaluation and Research (CBER)  
171st Meeting of the Vaccines and Related Biological Products Advisory  
Committee  
Silver Spring, MD  
March 3, 2022  
AGENDA**

<b>10:10am – 11:20am</b>	<p><b><u>Global Influenza Virus Surveillance and Characterization (70 Min)</u></b></p> <p><b>David Wentworth, Ph.D. (60 min)</b> Branch Chief, Virology, Surveillance, and Diagnostic Branch Influenza Division Centers for Disease Control and Prevention (CDC)</p> <p>Q &amp;A: 10 min</p>
<b>11:20am – 11:30am</b>	<b>BREAK (10 Min)</b>
<b>11:30am – 11:55am</b>	<p><b><u>DoD Vaccine Effectiveness Report (25 Min)</u></b></p> <p><b>LCDR. Courtney Gustin, M.S, (Nursing), Dr PH. (20 Min)</b> Global Emerging Infectious Surveillance Branch Armed Forces Health Surveillance Division Public Health Division - DHA</p> <p>Q &amp;A: 5 min</p>
<b>11:55am – 12:20pm</b>	<p><b><u>Candidate Vaccine Strains &amp; Potency Reagents (25 Min)</u></b></p> <p><b>Manju Joshi, Ph.D. (20 Min)</b> Lead Biologist Division of Biological Standards &amp; Quality Office of Compliance and Biologics Quality CBER/FDA</p> <p>Q &amp;A: 5 min</p>
<b>12:20pm – 12:45pm</b>	<p><b><u>Comments from Manufacturer Representative (25 min)</u></b></p> <p><b>Beverly Taylor, Ph.D. (20 Min)</b> Head of Influenza Scientific Affairs, WHO and IFPMA LEAD Seqirus -A CSL Company</p> <p>Q &amp;A: 5 min</p>

**FOOD AND DRUG ADMINISTRATION (FDA)**  
**Center for Biologics Evaluation and Research (CBER)**  
**171st Meeting of the Vaccines and Related Biological Products Advisory**  
**Committee**  
**Silver Spring, MD**  
**March 3, 2022**  
**AGENDA**

<b>12:45pm – 1:30pm</b>	<b>Lunch (45 min.)</b>
<b>1:30pm – 2:30pm</b>	<b>Open Public Hearing (60 min.)</b>
<b>2:30pm – 3:30pm</b>	<b><u>Committee Discussion, Recommendations, and Vote (60 Min)</u></b>
<b>3:30 pm</b>	<b>Adjourn the meeting- DFO</b>